Are High Urea Values before Intravenous Immunoglobulin Replacement a Risk Factor for COVID-19 Related Mortality?

Basit Öğe Kaydı
dc.contributor.authorAytekin, Gökhan
dc.contributor.authorAtayik, Emel
dc.date.accessioned2023-04-10T20:20:59Z
dc.date.available2023-04-10T20:20:59Z
dc.date.issued2022
dc.departmentRektörlük, Rektörlüğe Bağlı Birimler, Düzce Üniversitesi Dergilerien_US
dc.description.abstractAim: This study aimed to examine the data of the coronavirus disease 2019 (COVID-19) patients treated with intravenous immunoglobulin (IVIG) treatment and to investigate the effects of the patients' clinical, laboratory, and treatment characteristics and risk factors for mortality. Material and Methods: The study evaluated 81 adult COVID-19 patients who were hospitalized for the treatment of COVID-19 between April 2020 and September 2020 and were followed up, treated, and consulted in the immunology clinic for IVIG treatment, in a retrospective manner. Results: The univariate analyses revealed that the duration of hospitalization in service, being intubated, duration of IVIG treatment, and the urea value before IVIG treatment were related to mortality in COVID-19 patients treated with IVIG treatment. As a result of multivariate analysis, being intubated and urea value before IVIG treatment were found to be independent risk factors for mortality (p=0.001 and p=0.009, respectively). It was found that for the 60 mg/dL level of urea value before IVIG treatment to predict mortality, the sensitivity was 46.2%, and the specificity was 35.5%. The area under the curve was found as 0.647; 95% confidence interval 0.518-0.776 (p=0.029). Conclusion: The study found that urea values before IVIG treatment were a risk factor for mortality in patients who received IVIG treatment for COVID-19. This is important as it indicates that urea values should be closely monitored in patients given IVIG treatment for COVID-19. It also suggests that when resources are limited and risk stratification is required in COVID-19 patients, urea values can be helpful.en_US
dc.identifier.doi10.18678/dtfd.1066937
dc.identifier.endpage115en_US
dc.identifier.issn1307-671X
dc.identifier.issue2en_US
dc.identifier.startpage110en_US
dc.identifier.trdizinid1115663en_US
dc.identifier.urihttp://doi.org/10.18678/dtfd.1066937
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1115663
dc.identifier.urihttps://hdl.handle.net/20.500.12684/11503
dc.identifier.volume24en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofDüzce Tıp Fakültesi Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSARS-CoV-2en_US
dc.subjectimmunoglobulinen_US
dc.subjectmortalityen_US
dc.subjectblood urea nitrogenen_US
dc.subjectCOVID-19en_US
dc.titleAre High Urea Values before Intravenous Immunoglobulin Replacement a Risk Factor for COVID-19 Related Mortality?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11503.pdf
Boyut:
408.69 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Düzce Tıp Fakültesi Dergisi Koleksiyonu